Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
As we age, NAD+ levels naturally decline, leading to reduced cellular function and accelerated aging
However, oral bioavailability is significantly lower, and the effectiveness of oral Epithalon is not well-established
Through its regulation of stress response, modulation of neurotransmitters, neuroprotective effects, and anti-inflammatory properties, BPC-157 may promote positive mood and support healthy behavioral patterns
Preparing for Injection Wash your hands and clean your injection area
Disruptions in rhythm accelerate cellular aging, impair immune surveillance, and increase disease risk across all major systems of the body
available only through 503A compounding or research supply SNRI drugs covered / venlafaxine (Effexor XR) and duloxetine (Cymbalta) Primary interaction concern / overlapping serotonergic and vasopressive effects DDI severity grading / not classifiable (no human PK/PD interaction studies exist) Serotonin syndrome incidence with SNRI monotherapy / estimated 0.07 per 1,000 patient-years per pharmacovigilance data Venlafaxine CYP pathway / CYP2D6 (major), CYP3A4 (minor) Duloxetine CYP pathway / CYP1A2 (major), CYP2D6 (moderate) BPC-157 CYP interaction profile / unknown in humans
US$ 27.66
US$ 26.64
US$ 28.49
US$ 25.57
US$ 23.03
US$ 22.18
US$ 27.12
US$ 27.60
US$ 24.42
